An interventional study of Functional magnetic resonance imaging (fMRI) and Neuropsychological Assessments in Glioma and Brain Tumor Adult, sponsored by Brigham and Women's Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 853 studies in Glioma with a site in United States — 144 open to participants now, 231 under way, 6 of them phase 3. Glioma · United States.
Among the 853 studies in Glioma with a site in United States, this one is the 97th largest by planned enrollment of the 739 interventional ones that give a count, is one of 9 that started in 2027, is one of 86 with no phase, reaches primary completion later than 190 of the 230 other live ones, and was the 840th registered.
1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.
Browse Glioma studies →144 of the 853 studies in Glioma with a site in United States are open now. Recruiting first, the newest first:
Nuvation Bio Inc. · Sites in United States
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 1–21
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
Neonc Technologies, Inc. · Sites in United States
Ages 5–18
Children's National Research Institute · Sites in United States
Ages 3–25
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.
This study: 21 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
853 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 432 · Phase 2 321 · Phase 3 21 · Phase 4 6
First in 1979; this study’s year is marked. 9 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 32 across 1,078 interventional studies indexed under Glioma.
Median enrollment 30 across the 739 interventional studies, 69 across the 77 observational. Of the 564 that completed or were terminated, 203 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
172 of 853 have an industry lead sponsor. The 10 most frequent:
Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
Brigham and Women's Hospital has 2 studies filed under Glioma — fewer than ten, so there is no comparison to draw.
89 of the studies in Glioma with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT07814872Harvard Medical School (HMS and HSDM)A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | 2026-11 |
| NCT03510208Stanford UniversityPanitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery | 2026-11 |
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
Add all 89 to your calendar (.ics) → With an account.
Among the 853 studies in Glioma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research will compare a new type of functional MRI (fMRI) called naturalistic viewing (also called movie watching) to standard clinical fMRI techniques. Standard clinical fMRI currently uses multiple tasks such as reading and responding to words or sentences to determine which areas of the brain are responsible for language. Surgeons can use this information to help plan brain surgeries. This research will help determine if the movie-watching fMRI is equivalent or better than the standard task-based fMRI. If so, it could be useful for planning patients' surgeries in the future, without the need for multiple tasks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Functional magnetic resonance imaging (fMRI) · Behavioral: Neuropsychological Assessments
Functional magnetic resonance imaging (fMRI) is a type of non-invasive imaging that measures blood oxygen level-dependent (BOLD) signal changes in the brain when a task is performed (such as reading) or BOLD signal changes during resting or watching naturalistic stimuli (such as movie clips).
Also known as: fMRI
Neuropsychological assessments are standardized tests used to evaluate cognitive, behavioral, and emotional functions that reflect the performance of different brain systems. These tests can be on paper or on a computer.
Language localization
Sensitivity and specificity based on the proportion of activation within and outside of language regions-of-interest (ROIs).
Time frame: From enrollment to up to 6 months after brain surgery.
Language lateralization
Laterality index (LI) based on proportion of activation in the left vs. right hemisphere in language regions-of-interest (ROIs).
Time frame: From enrollment to up to 6 months after brain surgery.
FMRI language activations concordance with language fiber tracts
Concordance with language fiber tracts identified by diffusion MRI in terms of the Euclidean distance between fMRI language activations and the tracts.
Time frame: From enrollment to up to 6 months after brain surgery.
Quality metrics based on electrocortical stimulation (ECS)
Sensitivity and specificity computed relative to ECS positive/negative areas.
Time frame: From enrollment to up to 6 months after brain surgery.
Start is estimated for Jan 2027; primary completion for Mar 2029, 26 months later.
Of 131 non-industry interventional studies with no phase under Glioma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 114. This study's planned 26 months is below that.
Counting every sponsor, half of 142 studies reached it within 58 months; a quarter within 34 and three quarters within 114.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brigham and Women's Hospital →